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Although banned in most industrialized
nations, organochlorine (OC) pesticides are
still used in Third World countries and are
ubiquitous and persistent pollutants (1).
Dichlorodiphenyltrichloroethane (DDT) is
infamous as an endocrine disruptor in birds
(2), and the o,p´- isomer of DDT, which con-
stitutes approximately 15% of the technical
mixture, is estrogenic in vitro and in vivo (3).
Another estrogenic pesticide residue is the β -
isomer of hexachlorocyclohexane (HCH),
which constitutes 7–12% of technical HCH
(4). β -HCH has several toxicologic effects in
addition to estrogenic activity; also, it prefer-
entially accumulates in the fat of biota and
biomagnifies as it moves through the food
web (4). Because virtually all humans have
been exposed to these compounds, the con-
cern over their potential health effects contin-
ues to grow. Recent epidemiologic studies
have been controversial regarding the relation-
ship of OC blood levels and human disease
(5–16). The debate is likely to continue
because there are no “unexposed” cohorts for
comparison, and exposure information is dif-
ﬁcult to obtain. For these reasons, we must
rely on experimental animal studies as a guide
to determine rational safety levels for humans.
Many studies, both in vivo and in vitro,
probe a variety of effects caused by these
OC pesticides. Although β -HCH does not
competitively bind to the estrogen receptor
(17,18), it does produce a number of estro-
gen-like responses: it stimulates proliferation
and increases synthesis of progesterone
receptors in cultures of human breast cancer
cells (17,18), and it produces moderate
uterotrophic effects in the rodent uterus
(18,19). In contrast, o,p´-DDT does com-
petitively bind to the estrogen receptor
(18,20,21), and it produces a range of estro-
genic responses (18–23). However, previous
in vivo studies have used only a few or very
high doses of these chemicals, and only the
doses applied, not the resulting blood con-
centrations, were reported.
The present report describes an in vivo
experiment designed to correlate the estro-
genic end points of uterine epithelial cell
height (UEH) and vaginal epithelial thickness
(VET) with blood and fat levels of o,p´-DDT
and β -HCH in ovariectomized mice. To sim-
ulate the effect of chronic low-level exposure
seen in humans, a low dose, continuous
release system of Silastic capsules was
employed. A wide range of doses was admin-
istered, and concentrations of treatment com-
pound were measured in the blood and fat of
the mice. This is the ﬁrst study to correlate
blood and tissue concentrations of these com-
pounds to estrogenic response in laboratory
animals. These results are important to the
discussion of safe exposure for humans and
wildlife because they allow direct compar-
isons between blood levels and biological
responses.
Materials and Methods
Mouse treatment. All procedures performed
on animals followed the NIH Guide for the
Care and Use of Laboratory Animals (24), and
were approved by the Institutional Animal
Care and Use Committee of Indiana
University School of Medicine. Three weeks
after adult female CD-1 outbred mice were
ovariectomized, animals were treated with
o,p´-DDT or β -HCH over a dose range of
approximately 32-fold by subcutaneous inser-
tion of Silastic capsules containing crystalline
treatment compound. A positive control
group consisted of animals that received a
Silastic capsule containing 20 mg estrone
(Sigma Chemical Co., St. Louis, MO).
Negative control animals were treated with an
empty capsule. Treatment groups consisted of
five animals per dose. Treatment capsules
were made from Silastic tubing (1.6 mm i.d.,
3.2 mm o.d., and 14 mm length; Konigsberg
Instruments, Pasadena, CA) and sealed at
each end with Silastic cement. Each capsule
contained approximately 20 mg crystalline
material. Low doses were achieved by insert-
ing a single capsule containing treatment
compound mixed with crystalline cholesterol;
mixtures were prepared to make “dilutions”
of one-half, one-fourth, and one-eighth. The
higher doses were achieved by inserting two
capsules of the one-half dilution, or one, two,
or four capsules containing only test com-
pound. Each Silastic capsule was implanted
subcutaneously through a 5-mm slit on the
back. After 1 week of treatment, animals were
anesthetized and exsanguinated by heart
puncture. The uterus and vagina of each ani-
mal was removed for histomorphometric
determination of the estrogenic effect. Blood
serum and intraperitoneal fat samples were
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The effects of xenoestrogens have been extensively studied in rodents, generally under single,
high-dose conditions. Using a continuous-release, low-dose system in ovariectomized mice, we
correlated the estrogenic end points of uterine epithelial height (UEH) and vaginal epithelial
thickness (VET) with concentrations of two organochlorine pesticide isomers in fat and blood.
Silastic capsules containing a range of doses of either β -hexachlorocyclohexane (β -HCH) or o,p´-
dichlorodiphenyltrichloroethane (o,p´-DDT) were implanted subcutaneously, and animals were
killed after 1 week. Average blood levels achieved by the various doses were 4.2–620 ng/mL for
o,p´-DDT and 5.0–300 ng/mL for β -HCH. Fat concentrations of o,p´-DDT and β -HCH corre-
lated linearly to blood levels (o,p´-DDT, r 2 = 0.94; β -HCH, r 2 = 0.83). Fat concentrations
(nanograms per gram of tissue) were higher than blood concentrations (nanograms per milliliter)
by 90 ± 5- and 120 ± 9-fold (mean ± SE) for o,p´-DDT and β -HCH, respectively. The VET
ranged from 12 ± 0.9 µm in controls to 114 ± 8 µm in treated animals, and was correlated to
blood levels of either treatment compound. The UEH ranged from an average of 7.7 ± 0.3 µm in
controls to 26 ± 2 µm in high-dose o,p´-DDT-treated animals. The UEH was also correlated with
β -HCH concentration, but it plateaued at approximately 11 µm at the highest doses. The lowest
blood concentrations that produced statistically signiﬁcant increases in VET or UEH were 18 ± 2
ng/mL o,p´-DDT and 42 ± 4 ng/mL β -HCH. These values are within the same order of magni-
tude of blood concentrations found in some human subjects from the general population, sug-
gesting that human blood concentrations of these organochlorines may reach estrogenic levels.
Key words: β -HCH, dose response, histology, mouse, o,p´-DDT, uterine epithelium, vaginal epithe-
lium, xenoestrogen. Environ Health Perspect 108:973–977 (2000). [Online 7 September 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p973-977ulrich/abstract.htmlfrozen and saved for analysis of o,p´-DDT or
β -HCH concentrations.
Histomorphometrics. Uterine and vaginal
tissues were fixed in neutral formalin and
processed for parafﬁn sections. Tissue sections
(6 µm) were stained with hematoxylin and
eosin. Cross-sections were examined under a
light microscope (Nikon Optophot; Nikon,
Fryer Co., Huntley, IL) that was interfaced
with a Macintosh PowerPC computer (Apple
Computer, Inc., Cupertino, CA) through a
Sony 3CCD color video camera (Sony, The
Systems Group, Ann Arbor, MI). The height
of the uterine epithelium and the thickness of
the vaginal epithelium were determined using
an image analysis program (IPLab Spectrum,
Signal Analytics, Vienna, VA).
Blood extractions. Three or four of the
five blood samples from each dose were
processed for o,p´-DDT or β -HCH concen-
tration analysis. Approximately 100 µL
mouse serum was extracted three times with
20 mL hexane (EM Scientific, Gibbstown,
NJ). To increase the volume of the aqueous
phase, 1 mL of 90% formic acid (Fisher
Scientiﬁc, Fair Lawn, NJ) was added to the
serum. We used γ -HCH as an internal stan-
dard for the mice treated with β -HCH and
p,p´-DDT for the mice treated with o,p´-
DDT (Accustandard, New Haven, CT). The
resulting aqueous phase was extracted with 1
min of vortex mixing and 1 min of centrifu-
gation for each aliquot of hexane.
Fat extractions. Fat tissues (0.25 g) were
ground with 15 g of 10–60 mesh anhydrous
sodium sulfate (Fisher Scientiﬁc) and spiked
with the appropriate internal standard as
above. These mixtures were then Soxhlet
extracted for 24 hr in 300 mL 50% acetone
in hexane (EM Scientiﬁc).
Quality control. With each set of six sam-
ples, we also extracted a matrix spike and
either a matrix blank or a glassware blank. All
quality control samples underwent the same
cleanup procedure as the samples. The
matrix spike contained a known amount of
the target analyte similar in concentration to
what we expected in the samples. Spike
recovery averaged 104 ± 7%, and sample
concentrations were not corrected for recov-
ery. No target compound was found in any
type of blank; therefore, blank correction was
unnecessary.
Lipid analysis and removal. For fat sam-
ples only, lipid analysis was performed
gravimetrically in duplicate. The removal of
lipids was performed using a gel permeation
chromatography column. The glass column
(2.5 cm × 100 cm) was packed with SX8
Bio-Beads (Bio-Rad Laboratories, Hercules,
CA) and eluted with 60% cyclohexane in
dichloromethane (EM Scientific) at a flow
rate of 10 mL/min through the column.
The lipids were eluted in the ﬁrst 200 mL
fraction, whereas the HCHs and DDTs
were eluted in the following 400 mL
fraction.
Silica column cleanup. Sample extracts
were reduced to approximately 1 mL by
rotary evaporation and were exchanged into
hexane as necessary. Fractionation was per-
formed to remove possible interferences from
the samples. The extracts were run through a
silica (grade 923; Grace Davison, Baltimore,
MD) column (1.25 cm diameter) consisting
of glass wool, 20 cm of silica (1% HPLC-
grade water deactivated), and 1 cm sodium
sulfate. For both compounds, we collected
three fractions of 75 mL each. HCH samples
were fractionated with hexane, 50% dichloro-
methane in hexane, and dichloromethane,
whereas DDT samples were fractionated with
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Figure 1. Histology of vagina and uterus in treated mice. Shown are representative histologic sections of vagina (A, C,
E, G) and uterus (B, D, F, H) from mice treated for 1 week with an empty implant (A, B), an estrone implant (C, D), the
highest dose of o,p´-DDT (E, F), or the highest dose of β -HCH (G, H). The ﬁnal magniﬁcation is shown in each panel.
Darker cells labeled VE and UE are the measured vaginal epithelium and uterine epithelium, respectively. In the
estrone-treated (C) and o,p’-DDT-treated animals (E), there were several layers of keratinized cells in the superﬁcial
layers of the vaginal epithelium. 
(210× ) (420× )
(105× )
(420× ) (210× )
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(105× ) (420× )hexane, 20% dichloromethane in hexane, and
dichloromethane. The HCHs and DDTs
were eluted in the second fraction. All three
fractions were reduced by rotary evaporation
and solvent exchanged into hexane, if neces-
sary. The ﬁrst and third fractions were frozen
and stored, but not analyzed. The second
fraction was further reduced to approximately
50 µL by a gentle stream of nitrogen and
transferred into an autosampler vial with two
to three rinses of hexane.
Instrumental parameters. The samples
were analyzed on a Hewlett Packard 5890A
gas chromatograph (Hewlett Packard, Palo
Alto, CA) with an electron capture detector.
The carrier gas was hydrogen (80 mL/min
split vent, 2 mL/min on column) and the
makeup gas (25 mL/min) was nitrogen (Gas
Tech, Hillside, IL). Injections of 1 µL were
made by an autosampler in the splitless mode,
and the purge ﬂow (2 mL/min) was opened
after 3 min. We used a 60-m DB5 column
(J&W Scientiﬁc, Folsom, CA), with 250 µm
i.d. and a ﬁlm thickness of 0.1 µm, for separa-
tion. The temperature program for the DDTs
was 40°C for 1 min, ramped to 130°C at
30°C/min, ramped to 241°C at 3°C/min,
and ramped to 285°C at 30°C/min, with a
10-min hold for a total analysis time of 52
min. The HCH temperature program was
50°C for 1 min, ramped to 130°C at
20°C/min, ramped to 160°C at 1°C/min,
and ramped to 290°C at 30°C/min, with a 1-
min hold for a total analysis time of 40 min.
Statistical analysis. We used linear
regression analysis to compare blood and fat
concentrations of a compound to each other
and to compare biological response (VET or
UEH) against blood or fat concentrations of
a test compound. We used analysis of vari-
ance (ANOVA) and the Dunnett Test to
evaluate responses at each dose relative to
control (empty capsule treatment) response
values. Because variance increased with
increasing dosage, response values were log
transformed before applying ANOVA.
Results 
Estrogenic responses. The effects of the high-
est doses of each compound are shown in
Figure 1. o,p´-DDT increased VET to the
same extent as estrone. In addition, the
superficial layers of the vaginal epithelium
were keratinized in animals treated with
either estrone or o,p´-DDT. Uterine epithe-
lial cell height was also increased maximally
by o,p´-DDT. The effects of β -HCH were
less than those produced by estrone. The
highest dose of β -HCH produced kera-
tinized vaginal epithelium in only two of the
five animals in this group. However, there
was an apparent proliferative effect in the
other three animals, as evidenced by the
increased tissue thickness.
Blood and fat concentrations. Blood
concentrations of β -HCH and o,p´-DDT
averaged from 5.0 to 300 ng/mL and 4.2 to
620 ng/mL, respectively. Concentrations of
these compounds were much higher in fat,
1,300–42,000 ng/g tissue and 270–77,000
ng/g tissue for β -HCH and o,p´-DDT,
respectively. Figure 2 shows the strong linear
relationship between blood and fat concen-
trations for each compound, with fat 
concentrations related to blood levels by
coefﬁcients of 90 ± 5 and 120 ± 9 (SE) for
o,p´-DDT and β -HCH (r2= 0.94 and r2 =
0.83), respectively. 
Histomorphometrics. Control animals
had VET and UEH values of 11.7 ± 0.94 µm
and 7.7 ± 0.32 µm (mean ± SE), respectively.
VET was increased 10-fold by the highest
dose of o,p´-DDT and 5-fold by β -HCH at
its highest dose; however, the high dose of β -
HCH resulted in blood levels that were
approximately one-half those achieved by the
high dose of o,p´-DDT (Table 1). Thus, on a
nanogram per milliliter basis, o,p´-DDT and
β -HCH were equally effective in vaginal
epithelium. There was a linear correlation
between log blood concentration of either
compound and log VET or log UEH (Figure
3A-D); in each case the correlation was statis-
tically significant (p ≤ 0.002 for VET and
UEH against either o,p´-DDT or β -HCH).
As expected from the strong correlation
between blood and fat concentrations,
dose–response curves for VET and UEH
showed similar trends when plotted against
fat levels (not shown). Thus, only the blood
values are used for further discussions of
estrogenic responses.
For the purpose of comparison, animals
dosed with estrone had a VET (mean ± SE)
of 80 ± 7 µm and a UEH of 25 ± 3 µm
(Table 1). Mice with o,p´-DDT blood con-
centrations > 260 ng/mL had VET and
UEH responses as high or higher than the
estrone-induced effect. None of the β -HCH
treatments caused responses as high as those
achieved in estrone-treated animals; in fact,
the UEH response to β -HCH reached a
Articles • Effective levels of organochlorine xenoestrogens
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Figure 2. o,p´-DDT and β -HCH concentrations in fat and blood of (A) 20,000–100,000 ng/g wet wt and 0–1,000
ng/mL, respectively, and (B) 2,500–17,500 ng/g wet wt and 0–90 ng/mL, respectively. Linear relationships
were forced through the origin. The slope of the line (ng/g fat)/(ng/mL blood) indicates a magniﬁcation fac-
tor from blood to fat of 120 ± 9 for β -HCH and 90 ± 5 for o,p´-DDT (mean ± SE). Correlation coefﬁcients were
statistically signiﬁcant for both β -HCH (r2 = 0.83; p < 0.001) and o,p´-DDT (r2 = 0.94; p < 0.001).
Table 1. Blood concentrations and biological end points. 
Treatment group Blood concentration (ng/mL) UEH (µm) VET (µm)
Control 0 7.74 ± 0.32 (5) 11.7 ± 0.94 (5)
Estrone ND 25.5 ± 3.5 (5)** 79.6 ± 6.6 (5)**
o,p´-DDT
A (1/8) 4.4 ± 0.61 (4) 7.88 ± 0.62 (4) 14.3 ± 2.5 (4)
B (1/4)  5.2 ± 0.91 (3) 8.93 ± 0.22 (3) 14.7 ± 0.87 (3)
C (1/2) 23 ± 13 (2) 9.15 ± 0.66 (3) 20.0 ± 1.7 (4)*
D (2 ×  1/2) 18 ± 2.3 (3) 12.0 ± 0.95 (5)** 39.7 ± 7.0 (5)**
E (1) 190 ± 40 (4) 11.4 ± 1.6 (4)* 63.9 ± 10 (4)**
F (2) 260 ± 26 (4) 15.7 ± 1.9 (4)** 85.3 ± 21 (4)**
G (4) 620 ± 150 (4) 26.0 ± 1.7 (4)** 114 ± 8.4 (4)**
β -HCH
A (1/8) 5.0 ± 0.97 (3) 8.40 ± 0.61 (4) 12.1 ± 1.7 (4)
B (1/4) 12 ± 3.4 (3) 7.18 ± 0.75 (4) 15.1 ± 1.1 (4)
C (1/2) 22 ± 2.5 (3) 9.03 ± 1.2 (5) 17.6 ± 4.2 (5)
D (2 ×  1/2) 42 ± 3.6 (3) 9.97 ± 1.0 (4) 21.9 ± 2.7 (5)**
E (1) 66 ± 3.9 (3) 12.1 ± 0.61 (4)** 38.3 ± 6.1 (4)**
F (2) 170 ± 29 (4) 10.8 ± 0.71 (5)* 38.9 ± 2.9 (5)**
G (4) 300 ± 49 (4) 11.3 ± 0.82 (5)* 58.1 ± 5.2 (5)**
ND, not determined. Mean values of blood serum concentrations, UEH, and VET were determined for each
treatment/dosage group. For o,p´-DDT and β -HCH, dosage groups are listed as A–G for treatments with a single diluted
capsule (1/8, 1/4, 1/2), a single undiluted capsule (1), or multiple capsules (2 × 1/2, 2, 4). Values are presented as mean ±
SE; numbers in parentheses are the number of samples analyzed.
*p < 0.05. **p < 0.005 as compared to control.plateau of approximately 11 µm for blood
concentrations > 66 ng/mL (Table 1).
The doses in this experiment are low
enough to observe a no-observed-effect level
(NOEL). The lowest-observed-effect levels
(LOELs) in VET were detected at blood
concentrations of 42 ng/mL and 18 ng/mL
for β -HCH and o,p´-DDT, respectively
(Table 1). Statistically signiﬁcant increases in
UEH were detected at blood concentrations
of 66 ng/mL and 18 ng/mL for β -HCH and
o,p´-DDT, respectively (Table 1).
Discussion
Blood and fat concentrations. There is a
strong linear relationship between the blood
and fat concentrations for both compounds.
For β -HCH, fat levels (nanograms per gram
wet wt) were related to blood levels
(nanograms per milliliter) by a factor of 120;
fat levels of o,p´-DDT were related to blood
levels by a factor of 90. Similar trends have
been observed in humans. In a Canadian
study of paired blood and fat concentrations,
Mes (25) found 43- to 355-fold higher levels
of β -HCH in fat and a 33-fold higher level
of o,p´-DDT in fat. In an Indian study,
Ramachandran et al. (26) found 35-fold
(male) to 38-fold (female) higher levels of β -
HCH in fat and 20-fold (female) to 25-fold
(male) higher levels of o,p´-DDT in fat. The
linearity of these relationships allows us to
use either blood or fat values in our discus-
sion of estrogenic effects. Because blood lev-
els are more readily available in reports of
human exposure, we will focus on the blood
levels attained in our experimental system.
Dose–response curves. In general, β -HCH
produced a slightly lower response than did
o,p´-DDT across all blood levels observed.
There is a marked difference in the maximal
efﬁcacy of these compounds, especially in the
uterus. In both the uterus and vagina, o,p´-
DDT is more potent than β -HCH, produc-
ing a signiﬁcant effect at 18 ng/mL compared
to 42 ng/mL required for a signiﬁcant effect
by β -HCH. The observation that the uterine
response to β -HCH reached a plateau at
higher doses suggests that β -HCH is a com-
pound with differential effects of the vagina
and uterus. Nishino and Neumann (27) have
shown that two estrogen derivatives [8α -estra-
1,3,5(10)-triene-1,3,17β -triol and 1,3,17β -
triacetoxy-8α -estra-1,3,5(10)-triene]
produced estrogenic effects in the mouse vagi-
na, but not in the uterus. It may be that 
β -HCH also behaves in a selective manner,
having qualitatively different effects in the
vagina and uterus.
Concentration comparison to humans.
The biological response to the low levels of
these compounds was unexpected. Table 2
shows that the concentrations of OC 
pesticides in different unexposed human
populations were generally only 2.7–120
(o,p´-DDT) or 2–140 (β -HCH) times lower
than concentrations found to cause estro-
genic responses in mice. However, in Israel,
o,p´-DDT blood concentrations were found
to be as high as 32 ng/mL (28), nearly dou-
ble the minimal estrogenic blood level of 18
ng/mL observed in this study. Argentinean
pesticide workers had blood β -HCH con-
centrations as high as 240 ng/mL (29); this
is nearly six times the minimal estrogenic
level of 42 ng/mL found in this study. 
Although it is difﬁcult to determine if the
response in humans is the same as in mice, it is
alarming that the human blood concentrations
are so similar to the estrogenic concentrations
in mice. The mouse has proven to be a good
model for approximating estrogenicity of a
compound in humans. For example, although
the antiestrogens tamoxifen and clomiphene
show little estrogenicity in the standard uter-
ine weight and vaginal corniﬁcation bioassays
performed in the rat, they are fully estrogenic
in the mouse (30–33), and these compounds
behave as estrogen agonists in the human
uterus and vagina (34–36). Also, the mouse
model of developmental effects of estrogens in
the female and male reproductive tracts
accurately reﬂects the effects that diethylstilbe-
strol had on developing human reproductive
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Figure 3. UEH and VET dose–response curves for β -HCH (A and C, respectively) and o,p´-DDT (B and D,
respectively). Samples for which there were paired response and blood concentration values for β -HCH or
o,p´-DDT were used in log–log plots. Individual samples from the different dosages (1/8, 1/4, 1/2 … 4 cap-
sules) are shown with letters AA, BB, CC … GG, respectively, (compare treatment groups listed in Table 1).
The square of the correlation coefﬁcient, r2, for UEH was 0.39 for β -HCH (p < 0.002) (A) and 0.58 for o,p´-
DDT (p < 0.0001) (B). The r2 for VET was 0.75 for β -HCH (p < 0.0001) (C) and 0.87 for o,p´-DDT (p < 0.0001) (D).
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Table 2. Concentrations of β -HCH and o,p´-DDT reported in human blood.
Sample description β -HCH (ng/mL) o,p´-DDT (ng/mL)
Canada 1992a (25) ND–2.6 ND–0.27
India male 1982 (26) 0.30 ± 0.03 0.15 ± 0.02
Pakistan 1987 (28) 0–7.2 
Yugoslavia 1985–1986 (28) 1.7
Israel 1984–1985 (28) ND–32
United States (NOE) 1971a (29) 1.4 ± 0.46
Argentina (NOE) 1971a (29) 23 ± 10 0.27 ± 0.32
Argentina pesticide workers 1971a (29) 240 ± 140
Japan 1986–1988 (46) 0.7–5.5 
England 1967 (47) 4.1
Japanese in Florida (USA) 1971a (48) 14–17 1.5–2.2
Taiwanese in Florida (USA) 1971a (48) 3.6–21 Trace–6.6
Florida (USA) 1971a (48) 0.4 ± 2.0 0.7–2.0
India (NOE) 1992 (49) 13 ± 5.0
India pesticide workers 1992 (49) 33 ± 23 1.5 ± 4.5
Mice with estrogenic response (this study) 42 ± 3.6 18 ± 2.3
Abbreviations: ND, not detected (or below detection limit of the assay used); NOE, nonoccupationally exposed.
aNo sampling date was listed; therefore, the year of publication is given. tracts (37–39), whereas the tests performed in
a primate model were uninformative (40).
On the other hand, the choice of the outbred
CD-1 mouse may not have been optimum
for determination of estrogen sensitivity;
Spearow et al. (41) found that other strains
are much more sensitive to the effects of estra-
diol in the developing testes. Similarly, we
have found that strain differences can affect
the outcome of the rat vaginal bioassay for
xenoestrogen activity (42). Which strain of
mouse is most appropriate for comparison to
the human situation is not known, but cer-
tainly the results of the present study indicate
that blood levels of o,p´-DDT or β -HCH in
the nanograms per milliliter range have the
potential of producing estrogenic effects.
This study was designed to produce blood
and tissue levels of o,p´-DDT or β -HCH in
mice comparable to those found in people
from the general population, that is, those
who are not exposed through a job-related or
accidental event. Humans are exposed to OCs
on a daily basis through respiration, foods,
and contact (16). Additionally, circulating
levels may increase during periods of weight
reduction. As is generally seen in human 
studies, (25, 26), the concentration of OC
pesticides is much higher in fat stores. Fat
concentration is in equilibrium with blood
concentration; thus, during periods of
decreasing weight and fat stores, the com-
pounds in fat are released into the blood
stream and surrounding tissues (43,44).
Bigsby et al. (19) showed that this OC release
from fat can cause estrogenic responses in
mice. This is especially important in fatty
areas like the breast, in which the parenchyma
is the target of estrogenic compounds that
may act as tumor promoters (16,45).
This study is the ﬁrst to measure tissue or
blood levels of OC pesticide concentrations
and correlate them with estrogenic responses
in a laboratory animal. The extremely low
levels required to cause statistically signiﬁcant
effects compared to control animals were
unexpected. It is even more alarming that
there is little difference between these levels
and those that can be found in humans.
Future studies that include long-term, low-
dose exposure are required to simulate the
chronic low-level exposure seen in humans.
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